Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) Director Timothy A. Springer acquired 80,301 shares of the company’s stock in a transaction on Friday, October 4th. The stock was acquired at an average cost of $22.58 per share, for a total transaction of $1,813,196.58. Following the completion of the purchase, the director now directly owns 8,023,766 shares of the company’s stock, valued at approximately $181,176,636.28. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Cartesian Therapeutics Stock Performance
NASDAQ RNAC opened at $24.52 on Friday. Cartesian Therapeutics, Inc. has a 52-week low of $11.66 and a 52-week high of $42.60. The company has a 50-day simple moving average of $15.28 and a 200 day simple moving average of $19.77.
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $1.35. The company had revenue of $33.45 million for the quarter, compared to analysts’ expectations of $6.00 million. As a group, analysts anticipate that Cartesian Therapeutics, Inc. will post 3.99 earnings per share for the current year.
Wall Street Analyst Weigh In
Read Our Latest Analysis on Cartesian Therapeutics
Institutional Trading of Cartesian Therapeutics
A number of large investors have recently added to or reduced their stakes in RNAC. Artal Group S.A. purchased a new stake in Cartesian Therapeutics during the first quarter worth about $5,939,000. Vanguard Group Inc. purchased a new stake in Cartesian Therapeutics during the first quarter worth about $4,105,000. Delphi Financial Group Inc. bought a new position in Cartesian Therapeutics during the first quarter worth about $430,000. Logos Global Management LP bought a new position in Cartesian Therapeutics during the second quarter worth about $2,431,000. Finally, BNP Paribas Financial Markets bought a new position in Cartesian Therapeutics during the first quarter worth about $38,000. Hedge funds and other institutional investors own 86.95% of the company’s stock.
Cartesian Therapeutics Company Profile
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
See Also
- Five stocks we like better than Cartesian Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- The 3 Best Blue-Chip Stocks to Buy Now
- MarketBeat Week in Review – 9/30 – 10/4
- Investing In Automotive Stocks
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.